CA-QAD-INC
QAD Inc., a leading provider of next-generation manufacturing and supply chain solutions in the cloud, has opened registration for its new EMEA customer conference, QAD Transform Europe, a complimentary two-day event happening 24-25 September in Brussels, Belgium.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240514413631/en/
Customers, sponsors and other members of the QAD community will join manufacturing and supply chain leaders from across Europe for two days of networking, education and technology innovation. Attendees will hear from industry experts and peers about the state of manufacturing and supply chains, what the future may bring and how to stay adaptive.
“QAD Transform Europe is our fresh take on regional events designed for and tailored to the customer,” said QAD Chief Product and Marketing Officer Carter Lloyds. “We recognize that manufacturing and supply chain leaders continue to face uncertainty and change in their business. The only way to survive and thrive is to transform. We look forward to sharing our roadmap for transformation at the event.”
The agenda for QAD Transform Europe will address the fundamental reasons businesses need to transform to survive, and help map the journey to get there. QAD leaders will outline the company’s plans for how to navigate today and tomorrow and QAD customers will share their success stories.
Agenda Highlights:
- Introducing the Industrial Transformation Platform — QAD’s roadmap to help companies transform into an Adaptive Enterprise by QAD CEO Anton Chilton
- Panel discussion with industry leaders on the transformation imperative
- Effective change management across your organization
- Uncovering root causes — not symptoms — of supply chain disruption
- Keynote address on QAD’s technology strategy and the benefits of the Cloud with QAD CTO Tony Winter
- Keynote address on Artificial Intelligence with Jeroen Baert, Computer Scientist, Comedian, Geek
- Leveraging pragmatic AI in supply chains
- Aligning ESG and sustainability with commercial objectives
- QAD new flagship ERP release — ERP O³
- Product updates on QAD Redzone Connected Workforce, QAD GTTE, QAD SRM, QAD DSCP and QAD Process Intelligence
- The new QAD roadmap for the food and beverage industry
- Breakout sessions and QAD Sponsor Expo
On Day 1, QAD executives and guest speakers will share an update on QAD today and the Industrial Transformation Platform, a panel discussion with industry experts on the need for transformation, the QAD roadmap and customer success stories. A networking reception and dinner with fellow manufacturing and supply chain leaders will follow.
On Day 2, guest keynotes will present on Effective Change Management, followed by a presentation on the state of Artificial Intelligence. More great breakout sessions and a networking lunch with QAD will follow as well as a Sponsor Expo to see QAD solutions in action.
The full agenda can be accessed here. For the latest updates on QAD Transform Europe, follow us on social media and engage using #QADTransform.
Event Details
What: QAD Transform Europe Customer Conference
When: 24-25 September, 2024
Where: Cardo Brussels Hotel | Brussels, Belgium
Registration: To register to attend QAD Transform Europe, click here.
About QAD – Enabling Adaptive Enterprises
QAD Inc. is a leading provider of next-generation manufacturing and supply chain solutions in the cloud. To succeed in a turbulent world, facing disruptions in supply and fluctuations in demand, manufacturers and supply chains must rapidly respond to change and seamlessly optimize agility, efficiency, and resilience for effective customer service. QAD delivers Adaptive Applications to enable these Adaptive Enterprises.
Founded in Santa Barbara, California, QAD has customers in 84 countries around the world. Thousands of companies have deployed QAD enterprise solutions including enterprise resource planning (ERP), digital commerce (DC), supplier relationship management (SRM), digital supply chain planning (DSCP), global trade and transportation execution (GTTE), enterprise quality management system (EQMS), connected workforce and process intelligence. To learn more, visit www.qad.com or call +1 805-566-6100. Find us on LinkedIn, X, Facebook and Instagram.
“QAD” is a registered trademark of QAD. All other products or company names herein may be trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240514413631/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Kolmar Korea Named One of the TIME’s World’s Best Companies for Sustainable Growth26.12.2024 15:00:00 CET | Press release
Ranks 125th Among 500 Companies Around the GlobeTop 10% in the Environmental Sector Among 3,000 Major Global Companies Kolmar Korea (KRX: 024720) has been recognized by TIME Magazine as one of the World’s Best Companies for Sustainable Growth 2025. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241226863828/en/ Kolmar Korea on TIME's World's Best Companies in Sustainable Growth 2025 (Image: Kolmar Korea) On November 27, TIME, in collaboration with a global market research firm Statista, unveiled a list of the top 500 companies worldwide, demonstrating exceptional sustainable growth. Kolmar Korea took place 125th around the globe and 6th among Korean companies. Notably, it was the only Korean cosmetics company on the list, which featured a total of 23 Korean companies. The rankings were based on an evaluation of revenue growth, financial stability, and environmental impact, each contributing equally to a final score out of 10
Seoul Semiconductor: Philips Lighting Products Ordered to Recall 7-Year-Old Items26.12.2024 08:00:00 CET | Press release
The German District Court of Düsseldorf, on November 19 ruled in favor of Seoul Semiconductor (KOSDAQ:046890) in the patent infringement lawsuits, and also ordered that products manufactured by Philips Lighting and sold since March 2017 be recalled and destroyed. The Court also ruled that a fine of up to €250,000 would be imposed for each violation of this order. On December 17, the German Federal Patent Court also affirmed the validity of these patents, which solidifies the strength of many related patents. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225151382/en/ Application Examples with CRI 70 or Higher (Photo: Seoul Semiconductor) These court orders relate to the core technology used to achieve CRI 70 (Color Rendering Index 70%) or higher, applicable to all home lighting, automotive lighting products, IT flash, and backlights. Since the effects of these judgments are applicable to all products infringing on the pa
ispace-EUROPE and the Italian Space Agency (ASI) Sign Payload Services Agreement to Transport a Laser Retroreflector Array (LaRA2) on the Moon Surface26.12.2024 08:00:00 CET | Press release
Agreement Marks Significant Step Towards Increasing Italy’s Contribution to advancing Lunar Exploration ispace EUROPE S.A. (ispace-EUROPE), the Luxembourg-based subsidiary of ispace, inc., and the Italian Space Agency (ASI) have signed a payload services agreement to transport a Laser Retroreflector Array (LaRA2) to enable accurate position measurements on the Moon via laser ranging experiments, the two organizations announced today. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20241225137548/en/ The shape of LaRA2, a palm-sized dome (Photo: Business Wire) The agreement marks the first full-scale contract between ispace-EUROPE and ASI, with both organizations looking to joint future lunar development. LaRA2 is a small, robust, and lightweight instrument built to work without any power source and to survive the harsh surface conditions on the Moon for an extended period of time. It features a precise array of retroreflectors
Datopotamab Deruxtecan Application in the EU for Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer Voluntarily Withdrawn24.12.2024 08:00:00 CET | Press release
Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: AZN) have voluntarily withdrawn the marketing authorization application (MAA) in the EU for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients with locally advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) based on the TROPION-Lung01 phase 3 trial. The decision to withdraw the MAA was informed by feedback from the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA). Daiichi Sankyo and AstraZeneca will continue to work to bring datopotamab deruxtecan to patients with lung cancer in the EU who can benefit and are committed to unlocking the potential of this medicine in lung cancer through our robust clinical development program which includes seven pivotal trials in various lung cancer settings. Datopotamab deruxtecan is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly developed by Dai
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 1323.12.2024 22:05:00 CET | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Dr. Reshma Kewalramani, Chief Executive Officer and President, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 10:30 a.m. ET/7:30 a.m. PT. A live webcast of management's remarks will be available through the Vertex website, www.vrtx.com in the "Investors" section under the "News and Events" page. A replay of the conference webcast will be archived on the company's website. About Vertex Vertex is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious diseases. The company has approved medicines that treat the underlying causes of multiple chronic, life-shortening genetic diseases — cystic fibrosis, sickle cell disease and transfusion-dependent beta thalassemia — and continues to advance clinical and research programs in these diseases. Vertex also has a robust clinical pipeline of investigational
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom